Data as of Sep 15
| +0.05 / +0.52%|
The 3 analysts offering 12-month price forecasts for PDL BioPharma Inc have a median target of 8.00, with a high estimate of 8.00 and a low estimate of 7.00. The median estimate represents a -16.84% decrease from the last price of 9.62.
The current consensus among 3 polled investment analysts is to Hold stock in PDL BioPharma Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.